GlassScriptPhysician profile
Gerardo Chica
NPI 1790760940
$38,794.42
in general payments reported to CMS, 2019-2025
29 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $340 · 2021: $808 · 2022: $1,585 · 2023: $2,280 · 2024: $1,599 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,544 · Travel and Lodging: $727 · Education: $50.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.21 |
| Travel and Lodging | $727.44 |
| Education | $50.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $30,078.00 | 2019 | |
| Medtronic, INC. | $1,700.70 | 2022-2025 | Ellipsys Vascular Access System |
| Astrazeneca Pharmaceuticals LP | $1,558.37 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $720.18 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $701.62 | 2019-2025 | |
| Amgen INC. | $685.67 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $488.37 | 2021-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $441.46 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $317.50 | 2020-2024 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $304.74 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $289.73 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $211.71 | 2022-2025 | Benlysta, Jesduvroq, Arexvy |
| Ardelyx, INC. | $201.77 | 2024-2025 | Ibsrela |
| Cormedix INC. | $170.25 | 2024 | Defencath |
| Lilly USA, LLC | $136.81 | 2024-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $135.05 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $77.35 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $74.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $70.91 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $68.22 | 2021-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.48 | 2024-2025 | Jardiance |
| Mimedx Group, INC. | $54.92 | 2024 | |
| Mallinckrodt Hospital Products INC. | $54.08 | 2022-2024 | Acthar |
| Akebia Therapeutics INC | $46.59 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $43.33 | 2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $38.76 | 2021 | |
| Ascendis Pharma Endocrinology INC | $34.83 | 2025 | Yorvipath |
| Scpharmaceuticals INC. | $22.03 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.98 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Chica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.